


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hu et al.

Application Serial No.: 09/219,442

Filed: December 23, 1998

For: Vascular Endothelial Growth Factor 2



RECEIVED

Group Art Unit: 1646 DEC 21 1999
Examiner: Saoud, C. TECH CENTER 1600/2900

Atty. Docket No.: PF112P2D1

**ELECTION AND RESPONSE WITH TRAVERSE UNDER 37 C.F.R. § 1.143
AND PRELIMINARY AMENDMENT**

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

In response to the Official Action dated November 15, 1999, please consider the following amendments, traversal, provisional election, and remarks of the above-captioned application. Further, Applicants respectfully request entry and consideration of the following amendments prior to examination on the merits. Applicants submit concurrently herewith: (a) a Fee Transmittal, with appropriate fee; and (b) an Information Disclosure Statement and Form PTO-1449; and (c) Exhibits A and B. Please amend the application as follows.

In the Specification

Please amend the specification as follows.

On page 1, line 3, after "application is a" please insert -a divisional of U.S.

Application No. 08/999,811, filed December 24, 1997, now issued as U.S. Patent No. 5,932,540, which is^a.

On page 8, line 2, please delete the address "12301 Park Lawn Drive, Rockville, Maryland 20852" and replace with the ATCC's new address: --10801

University Boulevard, Manassas, VA 20110-2209.--;

12/20/1999 MBERME 00000021 083425 09213442

01 01103
02 01101

5274.00 CH
1014.00 CH